In this episode,Charles talks with Amber Tong, a senior editor at Endpoints News, about how the Biosecure Act could impact the biotech and pharma sectors.

Amber shares thoughts on how this law could change U.S.-China biopharma ties, jobs, and making medicines. We also look into how things are changing in this area, who might benefit or not, and the big global tensions that affect these shifts.

Here's what you are in for:

00:00 Introduction

00:33 Welcoming the Guest

02:36 Discussing the Biosecure Act

04:34 Impact on the Biotech Industry

07:17 Geopolitical Tensions and Historical Context

16:09 Potential Winners and Losers

35:16 Future Predictions and Conclusion

About Amber Tong

Amber Tong is a senior editor at Endpoints News, which is a global specialty publication covering the biotech and pharmaceutical industries. She's a reporter/editor with more than six years of experience covering the biopharma industry, with a particular focus on the growing role China plays on the global stage.

Amber is also at BIO San Diego 2024, go say hi.

Useful Information on BIOSECURE

Endpoints' latest articles:

BIO: China tensions, fixing gene therapy’s business model, and the stop-start market recovery

https://endpts.com/see-you-at-bio-china-tensions-fixing-gene-therapys-business-model-and-the-stop-start-market-recovery/

WuXi became a critical partner to biopharma companies. They’re not ready if the US cracks down

https://endpts.com/wuxi-became-a-critical-partner-to-biopharma-companies-theyre-not-ready-if-the-us-cracks-down/

The US could upend biopharma manufacturing. WuXi rivals have an opening

https://endpts.com/the-us-could-upend-biopharma-manufacturing-wuxi-rivals-have-an-opening/

US-China tensions threaten to ensnare additional Chinese biopharma contractors

https://endpts.com/us-china-tensions-threaten-to-ensnare-additional-chinese-biopharma-contractors/

New Biosecure draft features 2032 grandfather clause, five-year grace period for added companies

https://endpts.com/new-biosecure-draft-features-2032-grandfather-clause-five-year-grace-period-for-added-companies/

BIO CEO defends the organization's about-face on the Biosecure Act

https://endpts.com/bio-ceo-defends-the-organizations-about-face-on-the-biosecure-act/

Medicxi backs Chinese biotech's next-gen KRAS G12C drug with $40M injection

https://endpts.com/medicxi-backs-d3-bios-next-gen-kras-g12c-drug-with-40m-injection/

About Charles

Charles Spence leads...